KC

Comprehensive Study Notes: TB, Candidiasis, CMV, EBV

Tuberculosis - Overview
  • Causative agent: Mycobacterium tuberculosis. Tuberculosis (TB) is transmitted primarily through airborne spread.

  • Global burden: TB is the leading cause of death among people with HIV.

  • 2023 statistics: approximately 1.25 \times 10^6 deaths worldwide and 10.8 \times 10^6 diagnoses. In the United States, incidence has risen to above pre-pandemic levels.

  • Risk factors

    • Immunocompromised status

    • Immigration from high-risk countries

    • Immunosuppressive medication use

    • Healthcare worker

    • Unhoused

    • Illicit substance abuse

    • Prior history of TB

  • Disease progression

    • Primary infection: clinical illness directly after initial infection; most immunocompetent individuals mount an immune response to prevent progression to clinical illness by forming granulomas.

    • Secondary infection

    • Latent infection: equilibrium between host immune response and bacteria

    • Reactivation: latent infection activates to cause clinical illness

  • Primary infection (pulmonary TB)

    • Occurs soon after initial infection; majority asymptomatic

    • Symptoms (if present):

    • Atypical pneumonia features: fever, nonproductive cough

    • Chest imaging: unilateral lower-lobe patchy infiltrates or paratracheal/hilar lymphadenopathy

    • Tuberculous pleurisy with effusion: fever, cough, pleuritic chest pain, dyspnea; CXR shows unilateral pleural effusion

  • Latent TB

    • Asymptomatic

    • Approximately 5\text{--}15\% of patients progress to reactivation

  • Reactivation TB

    • Most common clinical form of TB

    • Symptoms develop over weeks to months: anorexia, weight loss, night sweats, low-grade fever, productive cough, hemoptysis, shortness of breath, pleuritic chest pain

  • Extrapulmonary TB

    • Accounts for about 20\% of newly recognized TB cases

    • More common in people with HIV or patients treated with TNF-alpha inhibitors

    • Common sites include meningitis, miliary TB, pericardial TB, cutaneous TB

  • Physical examination findings

    • Nonspecific: pallor, clubbing, wasting, dullness to percussion, crackles, decreased breath sounds

  • Diagnosis

    • Nucleic acid amplification testing (NAAT)

    • Xpert MTB/RIF: sputum sample; rapid TB diagnosis; detects rifampin resistance

    • Acid-fast bacilli smear microscopy

    • Ziehl-Neelsen stain: rapid TB diagnosis; cannot differentiate TB from nontuberculous mycobacteria

    • Mycobacterial culture

    • Gold standard; can assess drug susceptibility; may take up to 8 \text{ weeks} for results

    • Chest X-ray (CXR)

    • Helps differentiate primary infection from latent infection and reactivation

    • Primary infection: consolidation, hilar lymphadenopathy, Ghon focus (a small granulomatous lesion), Ghon complex (Ghon focus + regional lymph node involvement), Ranke complex (calcified Ghon complex)

    • Reactivation: upper lobe cavitary lesion, calcifications

    • Interferon-Gamma Release Assay (IGRA)

    • Serum blood test

    • Positive = TB infection likely; Negative = infection unlikely

    • Indeterminate results can occur with infection, inflammation, or immunosuppression

    • Tuberculin Skin Testing (TST)

    • 0.1 \text{ mL} purified protein derivative (PPD) injected intradermally

    • Reading required at 48–72 hours

    • Consider BCG vaccination history when interpreting results

    • TST interpretation and cutoff points

    • Interpretation depends on induration size (mm) and risk factors

    • General cut points:

      • Induration ≥ 5 \text{ mm}: positive in

      • People living with HIV

      • Recent contacts of people with infectious TB

      • People with fibrotic changes on CXR suggestive of prior TB

      • Transplant recipients

      • Other immunosuppressed patients (e.g., prolonged corticosteroids ≥15 \text{ mg/day} prednisone or TNF-α antagonists)

      • Induration ≥ 10 \text{ mm}: positive in

      • People born in countries with high TB prevalence (e.g., Mexico, Philippines, Vietnam, India, China, Haiti, Guatemala)

      • People who misuse drugs or alcohol

      • People who live or work in high-risk congregate settings (nursing homes, homeless shelters, correctional facilities)

      • Mycobacteriology laboratory workers

      • People with certain medical conditions (e.g., silicosis, diabetes, severe kidney disease, some cancers, certain intestinal conditions)

      • Children

Candidiasis - Overview
  • Most common form is candidiasis due to Candida albicans

  • Found on the skin, oropharyngeal cavity, GI tract, GU tract, and vagina (oropharyngeal candidiasis = thrush)

  • Risk factors

    • Antibiotic or corticosteroid use (especially inhaled)

    • Immunosuppression (e.g., HIV/AIDS, chemotherapy, organ transplant)

    • Diabetes mellitus (poor glycemic control)

    • Denture wearers (poor hygiene)

    • Xerostomia (dry mouth)

    • Infancy and old age

  • Signs and symptoms

    • Dry mouth

    • Dysgeusia (distorted taste)

    • Pain with eating

    • Fissures at the corners of the mouth

    • White patches on the mouth, tongue, and/or esophagus that are adherent, painless, and may be discrete or confluent

    • Patches scraped away reveal red, inflamed, and/or bleeding areas

  • Diagnosis

    • Clinically (often)

    • KOH preparation: budding yeasts/hyphae/pseudohyphae

    • Esophagogastroduodenoscopy (EGD): direct visualization of white mucosal plaque-like lesions

    • Look for underlying causes (HIV testing; HbA1c)

  • Treatment

    • Oropharyngeal candidiasis treatments:

    • Nystatin oral solution 100,000 \text{ U/mL}, 4\text{--}6 \text{ mL} PO every 6 hours for 7–14 days

    • Clotrimazole troches 10 \text{ mg} PO, 5 times daily for 7–14 days

    • Miconazole mucoadhesive buccal tablet, applied over canine fossa mucosa, PO once daily for 7–14 days

    • Systemic therapy: Oral fluconazole 100\text{--}200 \text{ mg} PO daily for 7–14 days

Cytomegalovirus (CMV) - Overview
  • Human herpesvirus 5 (CMV)

  • The majority of individuals have been infected by adulthood; transmission occurs through prolonged exposure to bodily fluids; possible routes include sexual, transplacental, perinatal, and blood transfusion.

  • Lifelong infection; establishes latency in myeloid cells, and reactivation occurs with immunosuppression

  • Congenital CMV is considered a TORCH infection.

  • Signs and symptoms

    • Immunocompetent:

    • Most are asymptomatic or present with mononucleosis-like syndrome (fever, chills, fatigue, malaise); incubation 20–60 days; duration 2–6 weeks; heterophile antibody negative

    • Immunocompromised:

    • Often asymptomatic but can present with viral syndrome (malaise, fever, leukopenia, thrombocytopenia)

    • Pneumonia (usually after bone marrow transplant or AIDS): fever, nonproductive cough, dyspnea

    • CMV retinitis (can lead to vision loss if untreated)

  • Diagnosis

    • CBC with differential: lymphocytosis with >10\% atypical lymphocytes

    • Monospot testing: negative

    • Serology: CMV IgM antibodies (indicates acute infection); CMV IgG antibodies (fourfold rise indicates active infection; CMV IgG antibodies alone indicate past infection)

    • Direct viral detection: CMV DNA (viral load), used especially in immunocompromised patients to monitor infection and treatment response

    • Chest X-ray: diffuse pulmonary infiltrates (if pneumonia)

    • Fundoscopy: retinal hemorrhages and cotton-wool spots, characteristic of CMV retinitis

  • Treatment

    • Immunocompetent: supportive care

    • Immunocompromised: antivirals

    • Ganciclovir IV or valganciclovir PO (duration typically 14–21 days)

    • Alternatives: Foscarnet, cidofovir

Epstein-Barr Virus (EBV) - Overview
  • Human herpesvirus 4

  • Infectious mononucleosis (mono)

  • Most common in early childhood; second peak in late adolescence/early adulthood

  • By adulthood, >90\% of people have been infected with EBV

  • Transmission and incubation

    • Highly contagious

    • Transmitted through saliva (most common, hence "kissing disease"), blood, bone marrow

    • Incubation period: 4\text{--}6 \text{ weeks}

  • Signs and symptoms

    • Infants and young children: often asymptomatic or mild pharyngitis/tonsillitis

    • Adolescents/young adults: prodromal phase with fatigue, malaise, myalgia; illness phase with fever, pharyngitis, palatal petechiae, lymphadenopathy (especially posterior cervical), rash, hepatosplenomegaly

    • Elderly: prolonged fever, fatigue, malaise, myalgia (symptoms can be more severe or atypical in older individuals)

  • Diagnosis

    • CBC with differential: leukocytosis, often with atypical lymphocytes

    • CMP: elevated liver enzymes, particularly transaminases

    • Heterophile test (Monospot): high specificity (\approx 100\%), \sim 80\text{--}90\% accuracy in the third week of illness; false positives possible earlier, false negatives in young children

    • Serology: viral capsid antigen (VCA) antibodies

    • Anti-VCA IgM: indicates acute infection

    • Anti-VCA IgG: indicates past infection

    • Other findings: rash can occur with Ampicillin/Amoxicillin use in patients with acute EBV infection, not directly caused by EBV itself but an interaction.

  • Treatment

    • Supportive care (rest, hydration, pain relief)

    • Avoidance of contact sports during acute illness due to risk of splenic rupture (especially if splenomegaly is present)

    • Glucocorticoids (in select scenarios, e.g., impending airway

Tuberculosis - Overview - Presentation:

  • Primary infection: Often asymptomatic. If symptomatic: atypical pneumonia features (fever, nonproductive cough), unilateral lower-lobe patchy infiltrates, or paratracheal/hilar lymphadenopathy. Tuberculous pleurisy: fever, cough, pleuritic chest pain, dyspnea; CXR shows unilateral pleural effusion.
  • Latent infection: Asymptomatic.
  • Reactivation (most common): Symptoms develop over weeks to months: anorexia, weight loss, night sweats, low-grade fever, productive cough, hemoptysis, shortness of breath, pleuritic chest pain.
  • Extrapulmonary: Accounts for about 20\% of cases; more common in HIV/TNF-alpha inhibitor patients. Can affect meninges, miliary (disseminated), pericardium, skin.
    • Diagnosis (Orders): Nucleic acid amplification testing (NAAT) like Xpert MTB/RIF, Acid-fast bacilli smear microscopy (Ziehl-Neelsen stain), Mycobacterial culture (gold standard), Chest X-ray (CXR), Interferon-Gamma Release Assay (IGRA), Tuberculin Skin Testing (TST).
    • Expected Results:
  • NAAT/AFB smear: Rapid diagnosis of Mycobacterium tuberculosis. AFB smear cannot differentiate TB from nontuberculous mycobacteria.
  • Mycobacterial culture: Confirms diagnosis, allows drug susceptibility testing; may take up to 8 \text{ weeks}.
  • CXR: Helps differentiate stages: Primary (consolidation, hilar lymphadenopathy, Ghon focus/complex, Ranke complex); Reactivation (upper lobe cavitary lesion, calcifications).
  • IGRA/TST: Indicate TB infection (latent or active); positive = TB infection likely. Interpretation of TST depends on induration size (e.g., ≥5 \text{ mm} for high-risk, ≥10 \text{ mm} for moderate risk) and patient risk factors.
    • Nuances:
  • Transmitted airborne. Progression from primary to latent to reactivation is common.
  • IGRA/TST detect infection, not necessarily active disease; culture/NAAT confirm active disease.
  • Leading cause of death among people with HIV, often presenting with extrapulmonary forms.
Candidiasis - Overview
  • Presentation:
    • Oropharyngeal candidiasis (thrush): Dry mouth, dysgeusia (distorted taste), pain with eating, fissures at the corners of the mouth. Characteristic white, adherent, painless patches on mouth, tongue, and/or esophagus. Patches scrape away to reveal red, inflamed, and/or bleeding areas.
  • Diagnosis (Orders): Clinical diagnosis (often), KOH preparation of scraped lesions, Esophagogastroduodenoscopy (EGD) for esophageal involvement. Investigation for underlying causes (HIV testing, HbA1c).
  • Expected Results:
    • KOH preparation: Budding yeasts/hyphae/pseudohyphae.
    • EGD: Direct visualization of white mucosal plaque-like lesions in the esophagus.
  • Nuances:
    • Most commonly caused by Candida albicans, a normal commensal organism.
    • Key risk factors: antibiotic/corticosteroid use, immunosuppression (HIV/AIDS, chemotherapy), diabetes mellitus (poor glycemic control), denture wearers.
    • The adherent white patches that scrape away are pathognomonic.
Cytomegalovirus (CMV) - Overview
  • Presentation:
    • Immunocompetent: Most are asymptomatic or present with a mononucleosis-like syndrome (fever, chills, fatigue, malaise); incubation 20\text{--}60 \text{ days}, duration 2\text{--}6 \text{ weeks}. Heterophile antibody negative.
    • Immunocompromised: Can present with viral syndrome (malaise, fever, leukopenia, thrombocytopenia), pneumonia (fever, nonproductive cough, dyspnea, often after bone marrow transplant or in AIDS), or CMV retinitis (can lead to vision loss).
  • Diagnosis (Orders): CBC with differential, Monospot testing, Serology (CMV IgM, IgG), Direct viral detection (CMV DNA/viral load), Chest X-ray (if pneumonia), Fundoscopy (if retinitis).
  • Expected Results:
    • CBC: Lymphocytosis with >10\% atypical lymphocytes.
    • Monospot testing: Negative (key differentiator from EBV).
    • Serology: IgM indicates acute infection; a fourfold rise in IgG indicates active infection; IgG alone indicates past infection.
    • CMV DNA (viral load): Used especially in immunocompromised to monitor infection and treatment response.
    • CXR: Diffuse pulmonary infiltrates (if pneumonia).
    • Fundoscopy: Retinal hemorrhages and cotton-wool spots, characteristic of CMV retinitis.
  • Nuances:
    • Human herpesvirus 5; establishes lifelong latency, reactivating with immunosuppression.
    • Causes mononucleosis syndrome that is Monospot negative, distinguishing it from EBV.
    • Congenital CMV is a TORCH infection.
    • Retinitis is a critical opportunistic infection in immunocompromised patients.
Epstein-Barr Virus (EBV) - Overview
  • Presentation:
    • Primarily causes infectious mononucleosis (mono).
    • Infants/young children: Often asymptomatic or mild pharyngitis/tonsillitis.
    • Adolescents/young adults: Prodromal phase (fatigue, malaise, myalgia) followed by illness phase with fever, pharyngitis, palatal petechiae, prominent lymphadenopathy (especially posterior cervical), rash, hepatosplenomegaly.
    • Elderly: May have prolonged fever, fatigue, malaise, myalgia; symptoms can be more severe or atypical.
  • Diagnosis (Orders): CBC with differential, CMP, Heterophile test (Monospot), Serology (viral capsid antigen [VCA] antibodies).
  • Expected Results:
    • CBC: Leukocytosis, often with atypical lymphocytes.
    • CMP: Elevated liver enzymes (transaminases).
    • Heterophile test (Monospot): High specificity for mono (\approx 100\%), \sim 80\text{--}90\% accuracy in the third week of illness; can be false negative in young children.
    • Serology (VCA antibodies): Anti-VCA IgM (indicates acute infection); Anti-VCA IgG (indicates past infection).
  • Nuances:
    • Human herpesvirus 4; commonly transmitted through saliva ("kissing disease").
    • Causes mononucleosis syndrome that is Monospot positive (distinguishing from CMV).
    • Risk of splenic rupture is critical in acute illness, requiring avoidance of contact sports if splenomegaly is present.
    • Rash can occur if Ampicillin/Amoxicillin is used, and it's an interaction, not a direct EBV symptom.